Category Archives: Online

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Fact Sheet Reveals Mexico’s Increasing Investment in Biopharmaceutical Sector

Leave a comment

A recent Global Health Progress fact sheet highlights how Mexico’s investment in its biopharmaceutical sector has spurred economic growth, fostered global competitiveness, reduced the health and economic burden of disease on local citizens, and improved access to medicines. With the tenth largest economy in the world, Mexico is currently investing more than 1% of its gross domestic product into its biopharmaceutical sector and this percentage is anticipated to increase as the country works to develop tomorrow’s medicines.

Like the U.S. and other big emerging markets, Mexico has recognized the potential of the biopharmaceutical sector to be an important source of economic growth through the creation of high-quality, high-skilled jobs. Currently, Mexico’s biopharmaceutical sector employs nearly 25,000 Mexican nationals at more than 32 biotechnology companies. The number of skilled workers entering the workforce is predicted to increase as more than 750,000 engineering and technology students in Mexico are currently enrolled in local universities. Additionally, collaboration between the public and private sector has resulted in the creation of more than 100 research centers.

Mexico’s emphasis on job creation stimulates the developments of new drugs, which improves access to medicines for its entire citizenry. For example, there are approximately 254 medicines in development or awaiting regulatory review for Mexican patients and Mexico currently ranks 19 out of 25 in terms of active clinical trial sites. The growth in share of global clinical trial sites can bring health benefits to Mexican patients, such as diffusion of medical knowledge, greater patience access to medicines and high quality care and effective medical practice.

Recognizing the potential for economic growth, improving access to medicines and inspiring drug innovation, the Mexican government has sought to implement policies to foster the growth of the sector. The National Council for Science and Technology, the principal government funding agency for scientific research in Mexico, provided approximately US $16 million to fund basic science projects between 2001 and 2004. Mexico also has several bioclusters, made up of biotechnology, biopharmaceutical and related companies, focused on pharmaceutical R&D. In addition, public-private partnerships between the Mexican government, academia and industry are increasing due in part to the government’s continued commitment to science and technology research and education.

Please view full PDF for additional information and list of sources.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Fact Sheet Projects China Will Become One of World’s Major Biopharmaceutical Players

Leave a comment

Data revealed in Global Health Progress’ (GHP) new fact sheet shows that China is projected to become one of the world’s major biopharmaceutical players, along with the U.S., Europe, and Japan, in the next fifteen years. This projection is based on China’s commitment to improving access to healthcare by expanding its biotechnology sector, increasing its exportation of biopharmaceuticals and investing in pharmaceutical research and development (R&D).

China has one of the fastest growing economies in the world with a gross domestic product of more than $8 trillion. Its biotechnology sector has become a bright spot in the Asia Pacific region and the world markets, with an impressive average annual growth rate of 19.4% between 2000 and 2005, and is anticipated to become the world’s third-largest pharmaceutical market in 2011, a major increase over its #8 rank in 2000

Part of China’s successful growth is due to its decision to improve access to healthcare by increasing exports of biopharmaceuticals. For example, in 2006 China exported a total of US $890 million in biopharmaceuticals – a 30.61% increase compared with the previous year. China has also become the largest vaccine manufacturing country in the world, capable of producing 41 vaccines to prevent 26 viral diseases, and has become the third country to succeed in large-scale production of genetically engineered insulin.

Additionally, China’s pharmaceutical R&D expenditures are expected to reach US $10 billion or 2% of global spending by the end of 2010. The country is expected to contribute an additional $40+ billion in annual sales by 2013, comparable to the level of increased sales forecast for the US market in the same period.

China’s investment in the biotechnology sector has translated into improvements regarding access to healthcare and the country’s economic growth through creating high-quality, highly skilled jobs. Currently, there are more than 500 biotechnology companies in China with the biopharmaceutical sector employing approximately 50,000 people. Additionally, pharmaceutical R&D is taking the form of multinational biopharmaceutical companies setting up research facilities in biotechnology parks in China, which can drive highly-skilled, high wage job growth and encourage better access to healthcare.

Please view full PDF for additional information and list of sources.

Via EPR Network
More Healthcare press releases

Alternative medicine, Business of Medicine, Drugs, Health Products, Healthcare Products, Medicine, Online, Pharmaceuticals, Society

Eastern Essentials Herbal Formulas- Premium Pharmaceutical-Grade Chinese Herbal Medicine

Leave a comment

California Licensed Acupuncturist and Master Herbalist, Jeremy Speiser, formulated all of our products, based on ancient Chinese herbal formulas, after years of painstaking studying, research and clinical practice. Time-tested ancient formulas were modified slightly by adjusting some of the ingredients and dosages to enhance its safety, focus and effectiveness.

Safety and Quality of Eastern Essentials Herbal Formulas:

All of the herbs we use are not just dried plant parts blended into a powder and then encapsulated or made into tablets like most other herb companies do. Many of the active ingredients will not be absorbed by the body, unless they are extracted first. We use herbs that are extracted using modern high tech equipment to create pharmaceutical grade extracts for maximum potency and absorption.

All of our formulas are:

100% Natural
Manufactured in an FDA inspected facility
Made of 5:1 concentrated herbal extracts that are manufactured under pharmaceutical grade GMP (Good Manufacturing Practices) guidelines

The raw herbs that make up our concentrated extracts are rigorously and consistently tested for:

Fingerprint of identity and quality with TLC (Thin Layer Chromatography) & HPLC (High-Performance Liquid Chromatography)
Macroscopic & Microscopic Analysis
Pesticide Residues
Microbial Levels
Aflatoxins
Heavy Metals
Foreign Material
Active or marker compounds
Infestation
Radiation

It is no wonder we obtain such amazing results!

Herb Formulas for:

Chronic Low Back Pain
Acute Low Back Pain
Upper Back Pain
Chronic Knee Pain
Acute Knee Pain
Shoulder Pain
Nervousness and Anxiety
Menopause Symptoms
PMS Symptoms
Premature Ejaculation
Threatened Miscarriage
Sinusitis and Congestion

http://www.easternessentials.com/

Via EPR Network
More Healthcare press releases

Alternative medicine, Business of Medicine, Diseases, Drugs, Health Products, Healthcare Products, Online, Pharmaceuticals, Society

Crohn’s Disease Nutritional Intake Help Found in Vitamin Gum

Leave a comment

Crohn’s disease help is not easy to find. That’s why the discovery of vitamingum is a newsworthy event for those afflicted. Because the disease affects the digestive tract, Crohn’s nutrition intake is a major concern. Sufferers often have little or no appetite due such pain, making it difficult for these individuals to intake and digest the vitamins and minerals needed.

vitamingum.jpg (300×200)

Edward Mugits, owner and developer of VitaBrew Coffee, contends that Vitamin gum is assisting his son with the needed Crohn’s nutrition intake. Mugits’ son has dealt with the disease for 20 years and according to Mugits he has never seen his son intake this level of nutrients and feel the difference he now enjoys. Chewing Vitamin Gum has not caused pain or suffering for Mugits’ son. As founder of VitaBrew Coffee, Mugits has over 1600 hours invested in Naturopathic studies. He is dedicated to research and development of healthy products and is always excited to share anything that will provide Crohn’s disease help.

The vitamin gum is readily available in stores across the nation; GNC, Walgreens, Express Mart, Five Below Stores, Follett Book Stores, Giant Eagle, Sheetz and Wilson Farms. Vitamin gum is available in three flavors: grape pomegranate, raspberry lemonade and peppermint ice. It is sugar free, offers fast absorption through the mucous lining and small intestine and only needs to be chewed for five to ten minutes to ensure release of the nutrients. Benefits include B vitamins, Vitamin D, Calcium and antioxidants.

Edward Mugits, owner and developer of VitaBrewcoffee.com Mugits is also the father of a son afflicted with Crohn’s disease and as such he understands the debilitation this disease can cause. Mugits is devoted to sharing whatever offers Crohn’s disease help. For his son, chewing vitamin gum has not caused any pain or suffering and is improving hit nutritional intake. Vitamin gum can help support the limited Crohn’s nutrition intake by providing antioxidants and vitamins that otherwise would be missed.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Russia Reveals Renewed Commitment to Expand, Promote Biotechnology Sector

Leave a comment

Global Health Progress (GHP) released a new fact sheet highlighting Russia’s commitment to expanding and promoting its biotechnology sector. Although the biopharmaceutical sector in Russia is less developed than other markets, the sector is making progress by implementing public policies that support pharmaceutical research and development (R&D) for life-changing treatments, contribute high-quality, high wage jobs to the region and increase the number of clinical trials offered to the population to improve access to drugs and help reduce the overall burden of disease.

Currently, Russia accounts for approximately 0.5% of the world biotechnology market, two-thirds of which are biopharmaceuticals. In 2010, the value of the biopharmaceutical market in Russia was estimated to be approximately US $17.2 billion, compared with US $10.4 billion in 2006. According to analysts, the Russian market is predicted to expand at a compound annual growth rate of 8.3% over the next few years and approximately 53% of the biopharmaceuticals market in Russia is comprised of innovative medicines.

As part of a national 10-year plan to promote biotechnology, the government is enacting policies to strengthen Russia’s pharmaceutical research and development (R&D) areas that have been historically strong. For example, special economic zones will focus on attracting investors to commercialize biotechnology and related innovations. Additionally, the Russian government is investing in “bioparks,” R&D clusters of biotechnology and related sectors.

Russia is well-known for its highly skilled scientific workforce and the biopharmaceutical sector has emerged as an important source of high-quality, highly skilled jobs. As the presence of biopharmaceutical companies increases, so does the pool of highly skilled doctors, scientists and researchers. According to Burrill & Company, the biopharmaceutical sector currently employs approximately 12,000 people with the average salary for a PhD scientist in Russia approximately US $1,800.

Currently, Russia ranks 12 out of 25 in terms of active clinical trials with 1,084 sites with an average relative annual growth rate of 33%. However, as of February 2010, there were 304 medicines in development in Russia, making the country one of the fastest annual growth rates. The growth in share of global clinical trials can bring health benefits, including the diffusion of medical knowledge and effective medical practice, greater patient access to high quality care and improve access to drugs. Clinical trials can also help reduce the overall burden of disease on the Russian population.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Brazil’s Biopharmaceutical Sector Contributes to Economic Growth, Expands Access to Healthcare

Leave a comment

Global Health Progress (GHP) released a new report that reveals how the biopharmaceutical sector in Brazil, the tenth largest biopharmaceutical market in the world and the largest in Latin America, is an important driver for its economy. For instance, Brazil’s biopharmaceutical sector develops high-quality, highly skilled jobs, which is a key factor in creating a stable economy. Currently, approximately 821 biotechnology companies in Brazil employ almost 100,000 people with an average annual salary of approximately US $4,457. Among those companies, six biopharmaceutical companies were featured in a 2003 list of the top 100 companies to work for in Brazil.

Not only does the biopharmaceutical sector produce valuable job opportunities for highly skilled workers, this emerging market plays a critical role in fostering public-private partnerships, which leads to more economic growth and greater access to healthcare for its citizens.

Investment in research and development (R&D) and promoting innovation are key ways the Brazilian government is helping drive future growth of the country’s biopharmaceutical sector. For instance, R&D investments in Brazil have increased to 1.5% of GDP in 2010 and there are more than 205 highly trained physicians per 100,000 of the population serving as investigators for clinical studies.

“In Brazil, promoting innovation is a public policy priority,” stated Rafael Oliva, Advisor to the Presidency at the Brazilian Development Bank. “The participation of the Brazilian government in research and development (R&D) is considerable, and the goal is to both increase innovative activities in Brazil on a systematic basis, and to consolidate the country’s culture of innovation.” GHP fact sheet shows how Brazil’s investment in research and development (R&D) will create positive effects throughout the economy, including improving access to healthcare for its citizens through the production of new medicines. The growing field of clinical trials is also a significant factor in improving access to healthcare. Brazil’s large population of 190 million people, with 8 out of every 10 residents living in or near a city, means clinical trial recruitment and participation is fairly robust.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Removing Intellectual Property Rights Will Only Worsen Africa’s Healthcare Crisis

Leave a comment

In recent commentary in the Wall Street Journal, Alec van Gelder, Project Director at the International Policy Network wrote that strong intellectual property rights are critical to strengthening Africa’s health care system. He criticized statements by the Head of the World Health Organization Essential Medicines Program, Hans Hogerzeil. Hoberzeil wrote that “Big Pharma” and intellectual property rights are preventing the world’s poorest countries from receiving access to healthcare. Contradicting these assertions, van Gelder pointed out that the region’s lack of health infrastructure and the diversion of aid money are the real culprits behind the crisis.

“Drug companies do make easy targets but that doesn’t make them villains,” said van Gelder, “The life-saving treatments they create remain Africa’s best hope. The misguided battle against pharmaceutical companies’ patent rights will only make Africa’s health crisis worse.”

van Gelder notes that the growing field of public-private partnerships have resulted in a twelve-fold increase in patients receiving treatment over the last decade and have created a program of voluntary patent licenses for lower-cost “generics” manufacturers. Furthermore, fewer than 5% of WHO’s 423 Essential Medicines are currently protected by patents and these are mostly advanced “second-line” anti-AIDS medicines.

Global Health Progress (GHP) is actively supporting public-private partnerships to help address the need for access to medicines. Strong patent protection and intellectual property rights are critical components of these efforts to treat the public health challenges that the world’s poorest countries face. As van Gelder aptly points out, “Trampling over intellectual property rights removes drug companies’ incentives to invest billions of dollars in the development of the next generation” of much-needed and sought after drugs.

Rather, GHP supports the continued development of public-private partnerships, research and development and protection for intellectual property rights. These policies ensure that developing countries continue to have drugs available at reasonable costs, that pharmaceutical companies continue to embrace innovations and that all organizations can work together to improve healthcare infrastructure worldwide.

Via EPR Network
More Healthcare press releases

Business of Medicine, Doctors, Health Products, Healthcare, Healthcare Products, Healthcare Professionals, Medicine, Online, Pharmaceuticals

Canadian Pharmacy Intermediary Save Rx Canada Upgrades Online Shopping System

Leave a comment

SaveRxCanada.com the premier Canadian pharmacy intermediary since 2004, announced an upgrade to its full online shopping system.

SaveRxCanada.com has been at the forefront of connecting consumers to affordableCanada drugs though its unique network of licensed Canada pharmacies and International online pharmacies.

SaveRxCanada.com has upgraded a number of features on its website (http://www.saverxcanada.com) to allow for better ease-of-use including an improved shopping cart, search tools, enhanced security with full digital encryption, and better customer service tools.

These improvements allow patients to securely order their medications online in a safe and easy way. Patients will also be able to create their own account without the need to print any documents, allowing orders to be processed and shipped faster.

The site also suggests how customers can adjust order size to maximize further savings. The improved shopping cart is also enhanced by exceptional customer service features. Customers can call toll-free or access a ‘live chat’ feature and have questions answered in real time by a ‘virtual’ customer service advisor.

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

‘Drugging the Undruggable’ Symposium Highlights Advances in Treating Cancer, Diabetes and Other Major Diseases

Leave a comment

Scientists from government, industry, and academia presenting at the 240th National Meeting of the American Chemical Society released a new report highlighting advances in creating the next generation of medicines for treating cancer, diabetes, and other major diseases. The report, which was featured during the special symposium, “Drugging the Undruggable,” summarized progress in drug development for diseases that were once considered “untouchable.” These treatments specifically targeted conditions where previous efforts to develop a drug therapyhad failed.

However, after decades of a seemingly impossible search, scientists appear to be making a breakthrough in the area of drug development to treat cancers and other diseases. As Science Daily noted in their coverage of the report and symposium, scientists have identified “stapled peptides,” a new family of potential drugs capable of blocking a key protein that’s involved in the development of cancer.

Global Health Progress (GHP) supports symposium presenters’ statements regarding the importance of these type of drug developments. For instance, Gregory Verdine, a chemical biologist at Harvard University, explained:

“The entire pharmaceutical industry has been working on drug-design platforms that focus on this little sliver of human drug targets and this limits the drug arsenal available to doctors. What’s required is an entirely new class of drugs that overcome the shortcomings of drugs of the past.” Innovative research and development (R&D) of new drugs is critical in improving overall healthcare, combating epidemics and fighting diseases. Drug development is just one way research-based biopharmaceutical companies serve as active partners in some of the largest and boldest health initiatives that explore new and effective ways to provide treatment, care and education to millions of people both domestically and internationally.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Medicines for Malaria Venture (MMV) Joins The Pool for Open Innovation Against Neglected Tropical Diseases

Leave a comment

Global Health Progress (GHP) is pleased to highlight the announcement that the not-for-profit public-private partnership Medicines for Malaria Venture (MMV) will became the first product development partnership (PDP) to contribute intellectual property to The Pool for Open Innovation against Neglected Tropical Diseases (The Pool).

MMV joined GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in providing intellectual property to The Pool. Discussing the decision, Professor Patrick Nef, Executive Vice President of Business Development at MMV, states, “In this way we hope to make fully available the know-how and technologies, assembled by MMV against malaria, for the research and development of innovative and efficacious treatments for other neglected diseases.”

By emphasizing a more accessible approach to intellectual property and know-how, The Pool facilitates access to patents and/or technologies for organizations that want to conduct research on treatments and motivates innovative and efficient drug discoveries and developments for neglected diseases.

The Pool is administered by BIO Ventures for Global Health (BVGH). It’s accessible to industry, non-profit institutions, and academic researchers who conduct research and drug development activities that deliver real benefits for patients in the least developed countries of the world.

Global Health Progress echoes the sentiment that MMV’s contribution of patents to The Pool, resulting from its research for new antimalarials, is an important milestone from an organization that plays a major role in leading the development of new therapeutics for malaria.

Global Health Progress supports the continuing partnership between not-for-profit public-private partnerships and research-based biopharmaceutical companies as a way to fight neglected tropical disease through targeted research and development (R&D), improving access to critical medicines and providing key intellectual property.

Via EPR Network
More Healthcare press releases

Alternative medicine, Business of Medicine, Drugs, Health Products, Healthcare Products, Online, Pharmaceuticals, Society

Better Vision with Natural Herbs

Leave a comment

Eyesight RX, natural eye formula developed by Dr. Ray Sahelian, M.D., is a revolutionary new vision support formula that may improve color perception, clarity of vision, day and night vision, distance vision, and the pleasure of looking at artwork, plants, nature. Eyesight Rx vision support supplies antioxidants to the tissues in the eye, including lutein, zeaxanthin, other carotenoids, and dozens of beneficial compounds that support and improve eye health.

About Advance Physician Formulas – Advance Physician Formulas, www.physicianformulas.com, provides science-based natural formulas developed by a medical doctor, top quality supplements with the highest grade raw material ingredients, along with reliable, honest, and friendly service.

About Ray Sahelian, M.D. – Dr. Sahelian has been writing about nutritional supplements for the over 20 years. His informative nutritional website, www.raysahelian.com is the highest visited site for vitamin news. Any information about vitamins typed in Google will bring up his website under the regular organic searches. Dr. Sahelian has written over 10 books about vitamins and nutritional supplements and sold over one million copies. His top two books, Mind Boosters and Natural Sex Boosters have helped thousands of people.

Via EPR Network
More Healthcare press releases

Healthcare, Healthcare Information, Healthcare Insurance, Healthcare Services, Online, Society

LifeInsurance.org Launches Key Information Designed to Take the Guess-Work Out of Choosing Your Life Insurance

Leave a comment

If you’re in the market for good quality life insurance at affordable prices either be whole life insurance or term life, be sure and take a look at LifeInsurance.org. Their comprehensive articles reveals information and all you need to know when searching for affordable coverage in your area.

To access the articles you are not required to give any personal information. If you are buying life insurance in the near future, all you need to do is simply input your zip code into the search box, and a list of the best and most reliable agencies in your area will appear.

Users can select a variety of insurance agencies and get free quotes in order to discuss the “ins-and-outs” of the market with someone knowledgeable in the field, and licensed to sell that coverage. With the laws governing life insurance varying from state to state it’s easy to fall victim to misinformation, to get confused, or to end up paying more thanyou should.

Shopping around is also the easiest way to save money, and to compare notes on different companies, different plans, and different rates. Life insurance is a long term investment that could potentially involve large sums of money, and choosing the right coverage is essential for protecting the people and assets that you could leave behind in the event of your sudden passing.

LifeInsurance.org is an entire site dedicated to offering information that clarifies the process of selecting life insurance, and offers users the ability to get that coverage at a great price. The site is full of details regarding Whole life insurance, Term life insurance, and Variable life insurance, including definitions, tips, and things to look out for.

Via EPR Network
More Healthcare press releases

Cosmetics, Dermatology, Diseases, Drugs, Healthcare, Healthcare Information, Medicine, Online, Pharmaceuticals, Public Health, Skincare, Society

New National Website Reaches Out To Millions Who Took Defective Acne Treatment Accutane

Leave a comment

Since 1982, 5 million Americans and 8 million persons in other countries were prescribed Accutane to fight severe acne. In doing so, they were exposed to a defective drug that’s caused serious intestinal injuries requiring surgery – even colon removal. Now Accutane is off the market in America, and Americans have a fighting chance to recover their medical and other expenses via Accutane lawsuits which already are prevailing in courts.

To launch the process, new legal website Accutane-Lawsuit-Lawyer.com is reaching out to Accutane victims needing representation for Accutane lawsuits in all 50 states. Such suits already have made news this year with jury verdicts favoring plaintiffs, including an Alabama man who received over $25 million for his Accutane-caused inflammatory bowel disease (IBD) which led removal of his colon.

Even Hollywood has entered the picture, via a recent Accutane lawsuit launched by actor James Marshall, star of TV’s Twin Peaks and the Oscar-nominated film A Few Good Men. After taking Accutane, Marshall, like many others, suffered an IBD and eventually had to have his colon removed. This severely impacted not only his health, but also his once-promising acting career.

The defective drug’s side effects even were referenced on a recent episode of the hit Fox TV series Glee.

Why has this happened? Indeed, why was it allowed to happen?

“Juries are finding that Swiss-based Roche Pharmaceuticals, creator of Accutane, knew that its product was unsafe but kept selling it anyway,” said a spokesperson for Accutane-Lawsuit-Lawyer.com. “Roche was making up to $1.2 billion per year in profits from Accutane. For Roche, eventual lawsuits were a trade off, and the human suffering was collateral damage.”

Juries are now holding that Roche did not adequately warn potential Accutane users of the drug’s serious side effects dangers. Thus, jury awards totaling more than $56 million already have been awarded in just a handful of Accutane lawsuits.

The Food and Drug Administration provides proof for such lawsuits. Though the FDA first approved Accutane’s use in 1982, the federal agency now calls Accutane’s active ingredient, Isotretinoin, “a potentially dangerous prescription medicine.” The FDA eventually required special warnings with Accutane.

Also in agreement is a Harvard University researcher who’s called Accutane “one of the most dangerous products on the market today.”

The FDA even has linked Accutane to such harmful side effects as severe depression, suicidal impulses and, for women who took Accutane during pregnancy, birth defects in babies. But for many sufferers, the problems involve an IBD such as Crohn’s Disease or ulcerative colitis. Each is a lifelong, incurable and debilitating digestive disorder – not to mention a costly one in terms of medical bills, lost salary and pain and suffering.

To recover such costs via an individual lawsuit – not a class-action suit — Accutane-Lawsuit-Lawyer.com says it can provide victims with an experienced Accutane defective drug lawyer in all 50 states of America. Many such suits may be handled in out-of-court settlements without a jury trial.

The legal website also has produced a special video for persons suffering acne to see. It demonstrates how-to tips on covering up acne with makeup, and advises against treating it with defective drug Accutane. The video can be viewed here: http://www.youtube.com/watch?v=YuptUKD_MGg

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Stresses Importance of Product Development Partnerships

Leave a comment

Helen Coster’s recent commentary in her new Forbes blog Good Work addresses the issue of how product development partnerships (PDPs) can develop and improve treatments for neglected diseases like malaria, leishmaniasis, and Chagas disease.

Coster notes, “These diseases affect the world’s poorest people, and they often get ignored by pharmaceutical companies for a simple economic reason: there is no way that considerable investment in research will be recouped in drug sales.”

Coster’s entry highlights the work of some of the best-known PDPs, such as the Drugs for Neglected Disease Initiative, Global Alliance for Vaccines and Immunization, the International AIDS Vaccine Initiative and the Global Fund to Fight AIDS, Tuberculosis & Malaria. Coster also highlighted the significant funding of PDPs by The Bill and Melinda Gates Foundation.

In closing, Coster invites her readers to discuss the PDP approach to eradicating neglected diseases and what role, if any, the pharmaceutical industry, philanthropists and other global organizations should play in the fight.

Global Health Progress also believes that public-private product development partnerships are invaluable in expanding the capacity of research and development (R&D) on innovative drugs and vaccines for neglected diseases. These partnerships help by harnessing the technical expertise and resources of the private sector with the approach of universities, research institutes and other public organizations.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Recent African Leaders Malaria Alliance Meeting Highlights Importance of Partnerships to Ensure Continued Progress on Malaria Vaccine

Leave a comment

During the recent African Union summit, the African Leaders Malaria Alliance (ALMA) gathered to discuss how to combat the threat of malaria in the continent. Inspired by this meeting, Madiké Seye, Vice-President for Africa – GlaxoSmithKline wrote a guest article on the Independent’s website calling for “new tools, such as a malaria vaccine, which could complement existing interventions.”

Seye wrote, “Vaccines and immunization services have been critical to improving Africa’s health over the last several decades. Anyone whose child has suffered f r o m malaria – and there are only few of us who have not directly been affected by the disease – can imagine what a malaria vaccine would mean.”

F r o m there, Seye highlighted the importance of partnerships between African leaders, policymakers, international groups and the pharmaceutical industry. These collaborations are required in order to move forward with making the dream of a malaria vaccine a reality, whether that’s through improving drug prices or investing in technology to fully develop the vaccine. Seye noted that the vaccine is already in the final phases of development and trial results have consistently shown an “acceptable safety profile.”

Global Health Progress supports the role of these public and private partnerships and the participation of the pharmaceutical industry, particularly when it comes to addressing issues involving drug prices, access to medicines, and the continued efforts to create innovative new drugs and vaccines. GHP believes research and development are especially critical components of improving health care and combating epidemics of neglected tropical diseases, such as malaria, in developing countries.

GHP echoes Seye’s call for countries, multilaterals, NGOs, the pharmaceutical industry and scientists to continue to work together to, “make sure Africa is ready for a vaccine. One day there may be the means to save many more lives and change the equation in the fight against malaria for good.”

Via EPR Network
More Healthcare press releases

Business of Medicine, Health Products, Healthcare, Healthcare Products, Healthcare Professionals, Medicine, Online, Pharmaceuticals

Foreign Pharmacy Intermediary MyGlobalPharmacy.com Launches Free Shipping Promotion for International Generics Program (IGP)

Leave a comment

MyGlobalPharmacy.com the premier international pharmacy intermediary launches its free shipping promotion for the International Generics Program (IGP).

MyGlobalPharmacy.com has been at the forefront of connecting consumers to affordable medications though its unique network of licensed international pharmacies and Canadian pharmacies. The International Generics Program (IGP) is another popular option for cash strapped consumers looking for additional savings. Consumers can now take advantage of free shipping for any IGP orders over $99.

MyGlobalPharmacy.com lists over 3000 medications including Canadian drugs, generic drugs and specialty cancer drugs.

Via EPR Network
More Healthcare press releases

Alternative medicine, Healthcare, Healthcare Information, Obesity, Online, Society, Weight loss

Study Reveals Significant Correlation Between Metabolism And Everyday Breathing

Leave a comment

According to a recent study released today, individuals with breathing problems, risk of asthma, and their prevalence in individuals whose weight exceeds healthy levels, is on-average 50 percent higher than those maintaining a healthy weight. The study, conducted in collaboration with The Laboratory of the Functional Reserves of the Human Body, Institute of Physiology of the Russian Science Academy, and Innovative Technologies Dept. and commissioned by BreathSlim, Inc., showed that respiration training had a significant impact on metabolism and an individuals ability to lose weight.

The results of the study, particularly those illustrating positive impact to Body Mass Index (BMI), corroborate BreathSlim’s decision to announce the launch of the new BreathSlim a weight loss system designed to modify the body’s traditional breathing cycle, expanding capacity through resistance training. Researchers observed that the average person utilizes 20 percent of oxygen upon inhalation. Training the respiratory system to increase oxygen absorption capacity through adaption of the body’s anti-hypoxia mechanisms, which include metabolism, ultimately contribute to increased weight loss.

“It’s never been easier to achieve a healthy lifestyle through reducing and maintaining a healthy weight. As our most recent study reveals the previously uncorrelated link between weight loss and everyday breathing is actually quite significant,” said Albert Shumoff, chief operating officer and global vice-president. “Moreover, BreathSlim is quick to implement and provides individuals with the methodology and lifestyle changes available today to improve their health and quality of life.”

Survey Key Findings
• 4 percent increase in oxygen absorption
• 3-5 percent improvement in BMI and 4.4-5.1 percent improvement in body fat

Survey Methodology
The study was conducted using volunteers in a three-phase breathing experiment utilizing the original form of equipment. The first phase used breathing through the nose, the second phase used pauses after inhalation, and the third phase used exhalation through the mouth with resistance. Each phase utilized varying combinations of time elapsed pre/post breathing cycle as well as water resistance. Observations were performed with subjects at a state of rest and collected in real-time, post one-month use, and post three-months. Observation methods used include anthropometry (e.g. measurements of height, weight, % of body fat, body mass index, control of blood pressure, heart rate) and spirography gas analyzer Oxyon-Pro Jaeger (e.g. breath volume, speed characteristics of breath, total gas analysis).

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Epitomizes Clinton, Gates’ Call for ‘Efficiency Savings’ In Regards to HIV/AIDS Prevention Treatments, Services

Leave a comment

During a recent international conference in Vienna for 20,000 AIDS scientists, health workers and activists, former U.S. President Bill Clinton and Microsoft founder Bill Gates urged AIDS activists to try to generate the most value possible out of funds set aside for HIV/AIDS prevention services and treatments, including securing access to drugs. Reuters Health and Science Correspondent Kate Kelland highlighted the leaders’ remarks in a recent article:

“The world is awash in troubles. It is easy to rail at a government and say … give us more money. But we also have to change the way we do what we do,” Clinton told the conference. “If we’re going to make this case, they (donor governments) have to believe that we are doing our job faster, better and cheaper. Then we have the moral standing to go ask people to give us more money.” Gates, a philanthropist whose Gates Foundation spends a large portion of its $34 billion fund on fighting AIDS, said efficiency was vital to be able to scale up access to AIDS drugs for the 15 million people who need them, “We can’t keep spending AIDS resources in exactly the same way we do today,” he said. “As we … advocate for more funding, we also need to make sure we’re getting the most benefit from each dollar of AIDS funding and every ounce of effort.”

In keeping with this message, Global Health Progress’ recent 3rd Annual African Health Delegation let African officials share experiences, expertise and insights about how they efficiently employ available resources when battling diseases in Africa. These conferences are just one way GHP helps advocacy groups meet Clinton and Gates’ plea for activists to employ “efficiency saving” tactics when delivering treatments and securing access to drugs for countries “hardest hit and at highest risk” by HIV/AIDs and other diseases.

Via EPR Network
More Healthcare press releases

Biotech, Business of Medicine, Diseases, Drugs, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Solutions, Medicine, Online, Pharmaceuticals, Society

Global Health Progress Highlights ViiV Healthcare’s Announcement of New Initiatives

Leave a comment

Global Health Progress highlights ViiV Healthcare’s announcement of a new series of initiatives, including improving access to medicines, to support people living with HIV/AIDS in the poorest and most vulnerable countries.

To address the evolving treatment needs in these countries, ViiV Healthcare will now allow people living with HIV/AIDS to access the whole portfolio of ViiV Healthcare antiretroviral medicines, produced by generic companies. Additionally, ViiV Healthcare is implementing the groundbreaking step of making all patents available to generic manufacturers in these countries for all future pipeline developments, such as the novel integrase inhibitor jointly under development Shionogi – ViiVHealthcare, LLC.

ViiV Healthcare is also expanding the number of countries eligible for this expanded access to medicines to include all least developed countries, all low income countries and all of sub-Saharan Africa – that is 80% of all people currently living with HIV. “At ViiV Healthcare we wanted to go one step further in addressing the HIV/AIDS crisis and supporting access for people living with HIV in the worst affected countries. As a company totally focused and dedicated to tackling this epidemic we are passionately committed to thinking and acting differently and taking new steps to expand access,” said Dr Dominique Limet, CEO of ViiV Healthcare, “At present the numbers of people in the least developed countries moving onto second line therapy is very low compared to the developed world. However as more people have access to treatment, there is an increased need for second and third line treatment options once initial treatment failure occurs.”

Via EPR Network
More Healthcare press releases

Business of Medicine, Drugs, Health Plans, Healthcare Information, Healthcare Insurance, Healthcare Services, Medicare, Medicine, Online, Pharmaceuticals, Public Health, Society

Medigap Plans Providing Prescription Drug Coverage Clarifications

Leave a comment

The MedicareSupplement.com News Center reported making a clarification that many are confused due to the name Medigap. Many seniors think that one of the “gaps” these Medicare insurance plans cover in traditional Medicare is prescription drug coverage. But they do not – at least all of the Medigap plans since the revamping of the plans in 2006, and more recent overhaul in June 2010, do not.

According to the website medicare.gov, prior to 2006, there were Medigap plans, notably H, I, and J, that did provide prescription drug coverage. These represent 3 out of the 4 Medigap plans that were eliminated in June 2010, only adding to the confusion. As explained on the Medicareinformational website, medicare.gov, Medicare Part D was introduced in 2006 to replace standardized Medigap polices that covered prescription drugs and to breakout prescription drug coverage from Medigap coverage. At that timepeople who were enrolled in one of the Medicare supplemental plans that had drug coverage were offered the choice of keeping those plans, changing them, or dropping the prescription drug coverage from them, and opting for Medicare Part D prescription drug coverage.

Since all lettered Medigap plans sold after 2006 did not offer prescription drug coverage, Medicare Part D is now the only prescription drug coverageavailable for seniors with original government Medicare and a Medigap plan. When purchasing prescription drug coverage only, to add to original Medicare, you are purchasing what is also known as a PDP, or Prescription Drug Plan. You may, during the open enrollment period, decide to switch out of original Medicare and into a Medicare Advantage plan with prescription drug coverage, also called a MA-PD.

If you have a pre-2006 Medigap plan that does have prescription drug coverage you still have a few options. If you are happy with that coverage you may continue to keep it and pay the premiums, EVEN IF THE PLAN HAS BEEN ELIMINATED.

You may also opt to switch to a Medigap plan that does not have prescription drug coverage, and then enroll in Part D. Many Medicare advisors believe this is advantageous, because the prescription drug benefits offered by Part D exceed those in the Pre-2006 Medigap plans, and you may actually be able to lower your monthly premiums, and improve your benefits by switching to one of the newly offered low-cost Medigap plans such as N or M, and then enrolling in Part D.

Also be advised that there are only certain enrollment periods for Medicare Part D; so do not drop any existing drug benefits until you are enrolled in Medicare D. For more information about Medicare, Medigap plans, and Medicare Part D, visit medicare.gov.

Via EPR Network
More Healthcare press releases